MADISON, Wis., Oct. 15, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced that, effective as of today, Suzanne Winter has returned from her temporary medical leave and assumed her full duties as President and Chief Executive Officer. Sandeep Chalke, who has served as interim CEO during Ms. Winter's absence, will continue in his position as Senior Vice President and Chief Commercial Officer."On behalf of the entire Board of Directors, I am delighted Suzanne has resumed her role as CEO. We ap ...

Accuray is the first industry partner to open a facility at the Genolier Innovation Hub, created to provide opportunities for clinician-industry collaborations that can help accelerate improvements in patient careNew Accuray CyberComm™ tool was used to significantly reduce the CyberKnife® S7™ System's commissioning time and enable product training in Genolier to begin more quicklyMADISON, Wis., Sept. 30, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the initiation of CyberKnife® S ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33301 1240 Deming Way Madison, Wisconsin 53717 (Address of Principal Executive Offices) (Zip Code) Registrants' telepho ...

Accuray Incorporated (ARAY) is well-poised for growth in the coming quarters, courtesy of continued robust demand for its products. The optimism, led by robust international performance in fourth-quarter fiscal 2024 performance and potential in the Precision Treatment Planning System (TPS) and Radiosurgery Market, is expected to contribute further. However, reimbursement uncertainties and stiff competition are concerning.This Zacks Rank #3 (Hold) company has lost 23% in the year-to-date period against 9.2% ...

Accuray Incorporated (ARAY) recently announced that Japan-based Gifu Prefectural General Medical Center became the first hospital in the country to treat patients with surface-guided radiation therapy (SGRT) using its Radixact Radiation Delivery System and VitalHold (ARAY’s joint solution in partnership with C-Rad) package. The technology is expected to play a crucial role in the hospital's plan to expand patient access to high-precision radiation therapy treatments.Per Accuray, high-resolution cameras cont ...

MADISON, Wis., Sept. 3, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that President and Chief Executive Officer Suzanne Winter will be taking a temporary medical leave of absence to receive care for a treatable form of cancer, effective immediately. Accuray Senior Vice President and Chief Commercial Officer Sandeep Chalke will serve as the interim CEO during Ms. Winter's absence. To ensure that Mr. Chalke and the organization have the necessary support, the company has formed an ...

Accuray公司相关 - Accuray公司的Accuray Helix系统获得CE标志可在全球市场部署是为满足新兴地区癌症治疗需求的高性价比方案[1] - 该系统注重可负担性、自动化和高通量能提高放疗计划和实施速度可用于多种癌症治疗有助于缩小全球癌症治疗差距[2] - 消息发布后Accuray公司股票在盘前交易中上涨近1%但今年以来已下跌17.3%而行业上涨8.5%标普500同期上涨17.8%[4] - 公司目前Zacks排名为3（持有）[5] 放疗行业相关 - 2023年全球放疗市场规模为74.7亿美元预计2033年将达到163亿美元复合年增长率为8.58%增长主要由癌症发病率增加放疗技术进步以及人们对先进疗法益处的认识提高等因素驱动[3] 其他医疗公司相关 - Universal Health Services公司Zacks排名为1（强力买入）估计长期增长率为19%过去四个季度盈利均超预期平均为14.58%今年以来涨幅为41.1%而行业涨幅为34.8%[5] - Quest Diagnostics公司Zacks排名为2（买入）估计长期增长率为6.20%过去四个季度盈利均超预期平均惊喜为3.31%今年以来涨幅为3.7%而行业涨幅为10.2%[5][6] - ABM Industries公司Zacks排名为2（买入）过去四个季度盈利均超预期平均惊喜为7.34%今年以来涨幅为24.1%而行业涨幅为11.9%[5][6]

Developed for India and other countries where patient access to care with radiotherapy is challenged and where versatility and ease of use are a high priorityDrives the next phase of company's strategic plan to expand its portfolio of helical radiation therapy delivery systemsMADISON, Wis., Aug. 27, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company has received CE Mark for Accuray Helix™, a CT-guided helical radiotherapy system designed to provide high-performance and high ...

baranozdemir Despite a well-received fiscal fourth quarter report that sent the shares up more than 50%, the reality is that Accuray (NASDAQ:ARAY) continues to struggle to show any real progress. This recently concluded fiscal year marked the third straight year of revenue in the $425M-$450M area, and the company has grown revenue by less than 2% a year over the past decade. While profitability has actually improved, the reality is that the shares have lost 25% of their value over the past five years (while ...

Accuray Incorporated (ARAY) and Halifax Health announced a breakthrough in cancer treatment at the Charles L. and Miki N. Grant Cancer Center for Hope in Port Orange, FL. The center's medical team became the first in the United States to treat cancer patients using Accuray’s Radixact System with VitalHold technology. This innovative system is designed to enhance the precision of radiation therapy by improving patient positioning and monitoring throughout the treatment process, offering a new standard of car ...